Stentys has announced that it has received the CE mark for the longest version (37mm) of its Xposition S sirolimus-eluting self-apposing stent. A press release reports that the approval of this longer version means that interventional cardiologists will now only need to implant a single self-apposing stent (in relevant longer lesions) rather than a long conventional stent, thus minimising the risk of malapposition and related complications.
According to the press release, the 37mm version of Xposition S is particularly well-suited to the treatment of lesions in the left main coronary artery and in tapered vessels. It notes that segments longer than 25mm have been demonstrated to have a higher degree of tapering (diameter difference of 0.5mm or more) and to be an independent predictor of acute stent malapposition with conventional stents.
Gonzague Issenmann, chief executive officer and co-founder of Stentys, comments: “We are very pleased to be able to offer cardiologists this new Self-Apposing drug eluting stent that is expected to increase our market share in the hospitals where we market our products.”
The Xposition stent portfolio already included three lengths—17mm, 22mm and 27mm.